基于基因多态性的术后舒芬太尼个体化镇痛给药剂量预测方程的构建

目的 构建患者术后舒芬太尼镇痛个体化给药剂量的预测方程。方法 对胃癌手术患者细胞色素P4503A4酶（cytochrome P450 enzyme，CYP450）*1G、儿茶酚胺氧位甲基转移酶（catechol-O-methyltransferase，COMT） Val158Met、阿片受体编码基因1（opioid receptor mu-1，OPRM1） A118G和多药耐药性蛋白（ATP-binding cassette sub-family B member-1，ABCB1） C3435T进行基因测序，并结合患者临床基本信息，建立胃癌患者术后舒芬太尼镇痛个体化给药预测方程，并代入肺癌手术患者信息进行验证。结果 胃癌患者术后舒芬太尼镇痛给药剂量y=4.104-0.222×[性别]+0.021×[OPRM1 A118G]+0.249×[ABCB1 C3435T]，将肺癌手术患者信息代入得出的预测方程，两者结果差异无统计学意义。结论 构建的患者术后舒芬太尼镇痛个体化给药预测方程有效，可供临床借鉴。

Establishment of Dose Prediction Equation of Postoperative Sufentanil Analgesia Administration Based on Gene Polymorphism

OBJECTIVE To establish a predictive equation for the individual administration of sufentanil for postoperative analgesia. METHODS Performed gene sequencing of the CYP4503A4*1G enzymes, COMT Val158Met, OPRM1 A118G, ABCB1 C3435T and combined with patient basic clinical information, established individualized dosage sufentanil analgesia postoperatively in patients with gastric cancer prediction equation, and taken the information of patients with lung cancer surgery for validation. RESULTS The predictive equation of postoperative sufentanil dosage in patients with gastric cancer was y=4.104-0.222×[gender]+0.021×[OPRM1 A118G]+0.249×[ABCB1 C3435T]. The information of patients with lung cancer surgery was substituted into the obtained predictive equation, and the results showed no significant difference with the actual dosage of sufentanil. CONCLUSION The prediction equation of postoperative sufentanil is effective and can be used for clinical reference.